Colorectal Cancer | Specialty

Dr. Le on Treatment Approaches for Oligometastatic Colorectal Cancer

March 19th 2020

Phat Le, MD, assistant professor, Department of General Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses treatment approaches for patients with oligometastatic colorectal cancer (CRC).

Dr. Putcha on the Utility of Blood-Based Assays in CRC

March 14th 2020

Girish Putcha, MD, PhD, discusses the utility of blood-based assays in colorectal cancer.

Dr. Armaghany on Gene Sequencing in CRC

March 13th 2020

Tannaz Armaghany, MD, discusses up-front gene sequencing in patients with colorectal cancer.

TAS-102 Plus Bevacizumab Is Potential New Option in Refractory mCRC

March 12th 2020

The addition of bevacizumab to TAS-102 (trifluridine/tipiracil; Lonsurf) reduced the risk of disease progression or death compared with TAS-102 alone in patients with chemorefractory metastatic colorectal cancer.

Dr. Nelson on the Benefit of Primary Tumor Resection in mCRC

March 11th 2020

Douglas A. Nelson, MD, associate professor in the Department of General Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the benefit of primary tumor resection in patients with metastatic colorectal cancer (mCRC).

Dr. Overman on Investigational Targeted Therapies in mCRC

March 11th 2020

Michael J. Overman, MD, professor in the Department of Gastrointestinal Medical Oncology of the Division of Cancer Medicine and committee vice chair at The University of Texas MD Anderson Cancer Center, discusses investigational targeted therapies in metastatic colorectal cancer (mCRC).

Advancing the mCRC Paradigm With Clinical Trials and Molecular Profiling

March 10th 2020

Kanwal Raghav, MBBS, MD, discusses the implications of molecular profiling on treatment decisions in metastatic colorectal cancer and the importance of referring patients to clinical trials.

Navigating NGS and Novel Therapies in GI Malignancies in New York

March 6th 2020

We recently traveled to Brooklyn, New York, for a State of the Science Summit™ on Gastrointestinal Cancer, which featured insights from Weill Cornell Medical Center and Montefiore Medical Center faculty.

Research in mCRC Underscores Importance of Individualized Approach

March 5th 2020

Michael J. Overman, MD, discusses the current treatment landscape of metastatic colorectal cancer and ongoing research efforts in the space.

Dr. Khan on Retrospective Analysis of Demographics in CRC and Gastric Cancer

March 4th 2020

Amir Khan, MD, discusses a large retrospective database analysis on colorectal cancer and gastric cancer presented at the 2020 Gastrointestinal Cancers Symposium.

Dana-Farber Tackles Rising Incidence of Young-Onset Colorectal Cancer

March 3rd 2020

Dana-Farber Cancer Institute launched the Young-Onset Colorectal Cancer Center, among the first of its kind, in March 2019 to provide expert and compassionate clinical care, promote scientific discovery and innovation to elucidate underlying biological mechanisms, identify risk factors, and facilitate development of novel therapies, and improve prevention and early detection by raising public awareness of the rising burden of CRC in young adults.

Dr. Raghav on Activating the RAS/RAF/MEK/ERK Pathway in CRC

March 3rd 2020

Kanwal Raghav, MBBS, MD, discusses the activation of the RAS/RAF/MET/ERK pathway in colorectal cancer.

Breathing New Life Into Chemotherapy

March 2nd 2020

Although the development of chemotherapy-free regimens is a major thrust of oncology research, improvements to traditional cytotoxic therapy are actively being explored, with a focus on new formulations and delivery methods for agents that have been used for decades.

FDA Approvals in HCC and Cervical Cancer, Breakthrough Designation in Lung Cancer, and More

February 26th 2020

The Future of MRD Assessment in CRC

February 26th 2020

Postsurgical ctDNA Surveillance in Locally Advanced CRC

February 26th 2020

Applying MRD Testing in Locally Advanced CRC

February 26th 2020

CRC: Incorporating MRD Testing Into Routine Practice

February 26th 2020

Potential Use of ctDNA and MRD in CRC

February 26th 2020

Revolutionizing Personalized Medicine in CRC

February 26th 2020